MARKET

ELVN

ELVN

Enliven Therapeutics Inc
NASDAQ
57.92
-0.86
-1.46%
After Hours: 57.65 -0.27 -0.47% 16:57 08/12 EDT
OPEN
59.09
PREV CLOSE
58.78
HIGH
60.38
LOW
57.68
VOLUME
1.01M
TURNOVER
--
52 WEEK HIGH
62.32
52 WEEK LOW
14.79
MARKET CAP
4.24B
P/E (TTM)
-34.7242
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at ELVN last week (0803-0807)?
Weekly Report · 2d ago
Analysts Offer Insights on Healthcare Companies: Tarsus Pharmaceuticals (TARS), Enliven Therapeutics (ELVN) and AMN Healthcare Services (AMN)
TipRanks · 5d ago
Enliven Therapeutics Price Target Raised to $82.00/Share From $80.00 by Stifel
Dow Jones · 6d ago
Enliven Therapeutics Is Maintained at Buy by Stifel
Dow Jones · 6d ago
Stifel Maintains Buy on Enliven Therapeutics, Raises Price Target to $82
Benzinga · 6d ago
Enliven Therapeutics Is Maintained at Buy by Guggenheim
Dow Jones · 6d ago
Enliven Therapeutics Price Target Cut to $78.00/Share From $80.00 by Guggenheim
Dow Jones · 6d ago
Guggenheim Maintains Buy on Enliven Therapeutics, Lowers Price Target to $78
Benzinga · 6d ago
More
About ELVN
Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. It is advancing two parallel lead product candidates, ELVN-001 and ELVN-002, and pursuing several additional research stage opportunities that align with its development approach. Its first product candidate, ELVN-001, is a potent, highly selective, small molecule kinase inhibitor designed to specifically target the breakpoint cluster region-Abelson (BCR-ABL) gene fusion, the oncogenic driver for patients with chronic myeloid leukemia (CML). ELVN-001 is an adenosine triphosphate (ATP)-competitive tyrosine kinase inhibitor (TKI). The Company's second product candidate, ELVN-002, is a potent, highly selective, central nervous system penetrant and irreversible human epidermal growth factor receptor 2 (HER2) inhibitor with activity against wild type HER2 and various HER2 mutations.

Webull offers Enliven Therapeutics Inc stock information, including NASDAQ: ELVN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ELVN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ELVN stock methods without spending real money on the virtual paper trading platform.